Abstract 367P
Background
MET amplification is a rare genetic mutation which can be treated with small-molecule inhibitor-crizotinib. Based on the detection of next-generation sequencing, the molecular characteristics and the efficacy of crizotinib among different subsets of MET amplification in lung cancer patients is poorly understood.
Methods
From January 2018 to April 2019, patients with MET amplification detected by next-generation sequencing were retrospectively collected and the efficacy of crizotinib among different subsets of patients were analyzed.
Results
In our study, 4.16% (112/2694) patients were found to have MET amplification and only 19 patients treated with monotherapy crizotinib. Among the 112 MET amplification patients, primary (with or without other mutation) MET amplification accounted for 3.27% (82/2507) and 16.04% (30/187) re-biopsy patients were found to have acquired MET amplification after the failed treatment of EGFR-TKI. The frequency of MET amplification combined with EGFR 21L858R was slightly higher than that of MET amplification combined with EGFR 19 del (primary or acquired). Primary MET amplification can occur simultaneously with EGFR 20ins or ALK rearrangement. In survival analysis, the median PFS of 10 patients with copy number greater than 4 (CN > 4) seems longer than the nine patients with copy number less than or equal to 4 (CN ≤ 4) (4.7 months vs 2.7 months) and the two curves were separate, but failed to get a statistical significance (p = 0.085). No significant difference has been discovered between the median PFS of primary (4.04 months; 95%CI: 0.33-7.74 months) and acquired (2.99 months; 95% CI: 2.51-3.47 months; P = 0.382) MET amplification.
Conclusions
4.16% lung cancer patients were found to have MET amplification based on the detection of NGS. MET amplification patients treated with crizotinib with copy number greater than 4 (CN > 4) seem have longer PFS. No obvious survival difference has been discovered between primary and acquired MET amplification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract